Lobe Sciences has cash of $5.85-million at Aug. 31

Executive Summary

• Lobe Sciences Ltd. reported its audited financial results for the fiscal year ended August 31, 2025, highlighting a significant strengthening of its balance sheet and liquidity position following a leadership transition and board renewal.
• The company completed a strategic financing at the subsidiary level for its lead asset, L-130, raising $8.46 million at a post-money valuation of $22.56 million, thereby avoiding significant dilution at the parent company level.
• Operational progress includes the completion of Phase 1a studies for L-130 (chronic cluster headache) and continued development of S-100 (sickle cell disease) through subsidiary Altemia Inc.

Key Details

• Cash Position: Cash increased to $5,854,118 on Aug. 31, 2025, compared to $237,772 on Aug. 31, 2024.
• Short-Term Investments: Held $1,686,688 in short-term investments on Aug. 31, 2025 (none reported in the prior year).
• Working Capital: Improved to a surplus of $5,163,526, compared to a deficit of $2,008,849 on Aug. 31, 2024.
• Debt Reduction: Convertible notes (current portion) decreased to nil on Aug. 31, 2025, from $641,374 on Aug. 31, 2024.
• Derivative Liability: Decreased to $205,105 on Aug. 31, 2025, from $603,724 on Aug. 31, 2024.
• Net Loss: Reported a net loss attributed to the parent company of $4,861,611 for fiscal 2025 (vs. $4,420,727 in fiscal 2024).
• Loss Per Share: Three cents for fiscal 2025 compared with four cents for fiscal 2024.
• Subsidiary Financing: Completed a financing for Cynaptec Pharmaceuticals Inc. (64% owned by Lobe) raising $8.46 million at a post-money valuation of $22.56 million.
• L-130 (Cynaptec): Lead program for chronic cluster headache; Phase 1a study in healthy volunteers and supporting preclinical work completed internationally; advancing development plan per FDA pre-IND guidance.
• S-100 (Altemia): Early-stage drug product candidate for sickle cell disease using a patented lipid-based delivery platform (docosahexaenoic acid and eicosapentaenoic acid).
• Commercialization: Preliminary commercialization activities for a proprietary medical food for sickle cell disease are ongoing, focusing on third-party reimbursement authorization.
• Market Cap: Remained below $5 million during fiscal 2025.

Notable Quotes

• "During fiscal 2025, our focus was on strengthening the company's financial position, reducing legacy liabilities and ensuring that our core assets were funded in a manner that preserved long-term shareholder participation. By advancing L-130 (psilocin mucate) through Cynaptec Pharmaceuticals Inc. and completing financing at the subsidiary level, we were able to secure capital for development while minimizing dilution at Lobe." — Dr. Frederick D. Sancilio, Chairman and CEO